Early Stage Oncology Biotech Files for $100 Million IPO

Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, announced today it has filed a registration statement with the Securities and Exchange Commission (SEC) relating to a proposed initial public offering of common stock.